USAF EA-2 en es it fr

Categorie

USAF EA-2 Les marques, USAF EA-2 Analogs

USAF EA-2 Les marques melange

  • No information avaliable
  • USAF EA-2 Formule chimique

    C8H6N4O5

    USAF EA-2 RX lien

    http://www.rxlist.com/cgi/generic/nitro25m.htm

    USAF EA-2 FDA fiche

    USAF EA-2 msds (fiche de securite des materiaux)

    USAF_EA-2 MSDS

    USAF EA-2 Synthese de reference

    Aucune information disponible

    USAF EA-2 Poids moleculaire

    238.157 g/mol

    USAF EA-2 Point de fusion

    263 oC

    USAF EA-2 H2O Solubilite

    79,5 mg / L

    USAF EA-2 Etat

    Solid

    USAF EA-2 LogP

    -0.04

    USAF EA-2 Formes pharmaceutiques

    Tablet

    USAF EA-2 Indication

    Pour le traitement de l'infection des voies urinaires

    USAF EA-2 Pharmacologie

    Nitrofurantoin, un nitrofurane agent antibactérien, est disponible sous forme microcristalline et macrocristallin pour traiter les infections des voies urinaires causées par de nombreuses bactéries gram-négatives et certaines bactéries Gram-positives.

    USAF EA-2 Absorption

    Aucune information disponible

    USAF EA-2 Toxicite

    Aucune information disponible

    USAF EA-2 Information pour les patients

    Patients should be advised to take Macrobid with food (ideally breakfast and dinner) to further enhance tolerance and improve drug absorption. Patients should be instructed to complete the full course of therapy; however, they should be advised to contact their physician if any unusual symptoms occur during therapy.

    Patients should be advised not to use antacid preparations containing magnesium trisilicate while taking Macrobid.

    Patients should be counseled that antibacterial drugs including Macrobid should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Macrobid is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Macrobid or other antibacterial drugs in the future.

    USAF EA-2 Organismes affectes

    Gram négatif et certaines bactéries Gram positives